RT Journal Article
SR Electronic
T1 TMS-induced plasticity improving cognitive control in OCD I: Clinical and neuroimaging outcomes from a randomised trial of rTMS for OCD
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.04.23298100
DO 10.1101/2023.11.04.23298100
A1 Fitzsimmons, Sophie M.D.D.
A1 Postma, Tjardo
A1 van Campen, A. Dilene
A1 Vriend, Chris
A1 Batelaan, Neeltje M.
A1 van Oppen, Patricia
A1 Hoogendoorn, Adriaan W.
A1 van der Werf, Ysbrand D.
A1 van den Heuvel, Odile A.
YR 2023
UL http://medrxiv.org/content/early/2023/11/05/2023.11.04.23298100.abstract
AB Background Repetitive transcranial magnetic stimulation (rTMS) is an emerging treatment option for obsessive-compulsive disorder (OCD). The neurobiological mechanisms of rTMS in OCD have, however, been incompletely characterized. We compared clinical outcomes and changes in task-based brain activation following three different rTMS stimulation protocols, all combined with exposure and response prevention (ERP).Methods In this three-arm proof-of-concept randomized controlled clinical trial, 61 treatment-refractory adult OCD patients received 16 sessions of rTMS immediately prior to ERP over 8 weeks, with task-based functional MRI (tb-fMRI) scans and clinical assessments pre- and post-treatment. Patients received either: high frequency (HF) rTMS to the left dorsolateral prefrontal cortex (DLPFC) (n=19 (6M/13F)); HF rTMS to the left pre-supplementary motor area (preSMA) (n=23 (10M/13F)); or control rTMS to the vertex (n=19 (6M/13F)). Changes in tb-fMRI activation pre-post treatment were compared using both a Bayesian region-of-interest and a general linear model whole-brain approach.Results Mean OCD symptom severity decreased significantly in all treatment groups (delta=- 10.836, p<0.001, 95% CI [-12.504, -9.168]), with no differences between groups. Response rate in the entire sample was 57.4%. Groups receiving DLPFC or preSMA rTMS showed, respectively, a decrease in planning and error processing task-related activation after treatment that was associated with symptom improvement, while individuals in the vertex rTMS group with greater symptom improvement showed an increase in inhibition-related activation.Conclusions PreSMA and DLPFC rTMS combined with ERP led to significant symptom improvement related to activation decreases in targeted task networks, although we observed no differences in symptom reduction between groups.This trial was registered at clinicaltrials.gov (NCT03667807)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03667807Funding StatementThis study was supported by a VIDI grant (91717306, awarded to OvdH) from the Netherlands Organization for Health Research (NWO/ZonMw). SMDDF was financially supported by the Netherlands Organization for Health Research (NWO/ZonMw, VIDI grant (91717306) to OAvdH); TSP is supported by National Health Care Institute (ZINL/ZonMw VeZo grant 80-86200-98-20006); YDvdW by a NIA Award No. 1R01AG058854-01A1, NINDS award 1RO1NS107513-01A1, a Proof of Concept fund from Amsterdam UMC, in addition to the NWO/ZonMw VIDI grant (91717306), and ZINL/ZonMw VeZo grant (80-86200-98-20006), OAvdH is supported by the National Institute of Mental Health (NIMH) R01 grant (R01MH113250-01) and International OCD Foundation (IOCDF) Innovation grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of VU Medical Center (VUmc), Amsterdam, The Netherlands, gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDatasets are not available to share